These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29572186)

  • 21. Angiogenic protein expression in advanced epithelial ovarian cancer.
    Barton DP; Cai A; Wendt K; Young M; Gamero A; De Cesare S
    Clin Cancer Res; 1997 Sep; 3(9):1579-86. PubMed ID: 9815846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer.
    Alberti C; Pinciroli P; Valeri B; Ferri R; Ditto A; Umezawa K; Sensi M; Canevari S; Tomassetti A
    Oncogene; 2012 Sep; 31(37):4139-49. PubMed ID: 22158046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer.
    Dobrzycka B; Mackowiak-Matejczyk B; Terlikowska KM; Kulesza-Bronczyk B; Kinalski M; Terlikowski SJ
    Eur Cytokine Netw; 2013; 24(3):106-13. PubMed ID: 24197277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
    Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
    Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low levels of ADAM23 expression in epithelial ovarian cancer are associated with poor survival.
    Ma R; Tang Z; Sun K; Ye X; Cheng H; Chang X; Cui H
    Pathol Res Pract; 2018 Aug; 214(8):1115-1122. PubMed ID: 29921495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel glycobiomarker for ovarian cancer that detects clear cell carcinoma.
    Sogabe M; Nozaki H; Tanaka N; Kubota T; Kaji H; Kuno A; Togayachi A; Gotoh M; Nakanishi H; Nakanishi T; Mikami M; Suzuki N; Kiguchi K; Ikehara Y; Narimatsu H
    J Proteome Res; 2014 Mar; 13(3):1624-35. PubMed ID: 24498956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression.
    Kurosaki A; Hasegawa K; Kato T; Abe K; Hanaoka T; Miyara A; O'Shannessy DJ; Somers EB; Yasuda M; Sekino T; Fujiwara K
    Int J Cancer; 2016 Apr; 138(8):1994-2002. PubMed ID: 26595060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The conglomeration of diagnostic, prognostic and therapeutic potential of serum miR-199a and its association with clinicopathological features in epithelial ovarian cancer.
    Zuberi M; Khan I; Gandhi G; Ray PC; Saxena A
    Tumour Biol; 2016 Aug; 37(8):11259-66. PubMed ID: 26951510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum soluble mesothelin-related peptide (SMRP): a potential diagnostic and monitoring marker for epithelial ovarian cancer.
    Wu X; Li D; Liu L; Liu B; Liang H; Yang B
    Arch Gynecol Obstet; 2014 Jun; 289(6):1309-14. PubMed ID: 24370956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sprouty 2 protein, but not Sprouty 4, is an independent prognostic biomarker for human epithelial ovarian cancer.
    Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
    Int J Cancer; 2015 Aug; 137(3):560-70. PubMed ID: 25630587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preoperative angiopoietin-2 serum levels: a marker of malignant potential in ovarian neoplasms and poor prognosis in epithelial ovarian cancer.
    Sallinen H; Heikura T; Laidinen S; Kosma VM; Heinonen S; Ylä-Herttuala S; Anttila M
    Int J Gynecol Cancer; 2010 Dec; 20(9):1498-505. PubMed ID: 21119365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer.
    Siddiqui GK; Maclean AB; Elmasry K; Wong te Fong A; Morris RW; Rashid M; Begent RH; Boxer GM
    Angiogenesis; 2011 May; 14(2):155-61. PubMed ID: 21221762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.
    Bandiera E; Zanotti L; Fabricio AS; Bucca E; Squarcina E; Romani C; Tassi R; Bignotti E; Todeschini P; Tognon G; Romagnolo C; Gion M; Sartori E; Maggino T; Pecorelli S; Ravaggi A
    Clin Chem Lab Med; 2013 Sep; 51(9):1815-24. PubMed ID: 24013103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of IL-10 and TGF-β levels and myeloid and lymphoid dendritic cells in ovarian cancer patients.
    Wertel I; Polak G; Tarkowski R; Kotarska M
    Ginekol Pol; 2011 Jun; 82(6):414-20. PubMed ID: 21853929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.
    Kraft A; Weindel K; Ochs A; Marth C; Zmija J; Schumacher P; Unger C; Marmé D; Gastl G
    Cancer; 1999 Jan; 85(1):178-87. PubMed ID: 9921991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tyrosine kinase A receptor (trkA): a potential marker in epithelial ovarian cancer.
    Tapia V; Gabler F; Muñoz M; Yazigi R; Paredes A; Selman A; Vega M; Romero C
    Gynecol Oncol; 2011 Apr; 121(1):13-23. PubMed ID: 21236475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical significance of vascular endothelial growth factor in malignant ascites.
    Zhan N; Dong WG; Wang J
    Tumour Biol; 2016 Mar; 37(3):3719-25. PubMed ID: 26462841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CDKN3 is an independent prognostic factor and promotes ovarian carcinoma cell proliferation in ovarian cancer.
    Li T; Xue H; Guo Y; Guo K
    Oncol Rep; 2014 Apr; 31(4):1825-31. PubMed ID: 24573179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro.
    Kim S; Gwak H; Kim HS; Kim B; Dhanasekaran DN; Song YS
    Oncotarget; 2016 Dec; 7(50):83148-83159. PubMed ID: 27825119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.